journal cover

Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice

Metabolism: Clinical and Experimental

Jan 10, 2012

Michishige TerasakiTsutomu Hirano

Abstract

We recently discovered that glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide can both prevent the development of atherosclerosis in apolipoprotein E-null (Apoe(-/-)) mice. In the present study, we attempted to extend these findings to orally administered dipeptid...read more

Mentioned in this Paper

Macrophages, Peritoneal
Glucagon (rDNA)
Epicholesterol
ZGLP1 wt Allele
Apolipoprotein Measurement
Systolic Blood Pressure Measurement
Analog
Pyrrolidines
Total cholesterol
LDL-1
Paper Details
References
  • References10
  • Citations30
1
  • References10
  • Citations30
123

Similar Papers Found In These Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Parkinson's Disease

Parkinson's Disease is a progressive neurodegenerative disorder characterized by loss of muscle control, including trembling of the limbs and impaired balance. Here is the latest research.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Neuropeptides

There are >50 peptides released by neurons that function as neuromodulators, neurotransmitters, neurohormones, and hormones. Here is the latest research on the systemic function of neuropeptides in the body.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Cerebrovasculature & ApoE

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of neurodegenerative and cardiovascular diseases. This feed focuses on the role of this protein in cerebrovasculature and cerebrovascular dysfunction.

GLP-1 Signaling

GLP-1 signaling pathway has been well studied for its role in regulating glucose homeostasis, as well as its beneficial effects in energy and nutrient metabolism. Discover the latest research on this signaling pathway here.

Inosine: Parkinson's Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects movement. Drug Inosine is proposed to slow progression of this disease. Here is the latest research on Inosine in PD.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's Disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's Disease here.

Secondary Parkinson disease

Secondary Parkinson disease refers to a group of disorders that present similarly to Parkinson disease but have different etiology. Secondary Parkinson disease is caused due to the blockade of or interference in dopamine’s action in the basal ganglia. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Ganglioside & Cholesterol Absorption

Gangliosides are sialic acid-containing glycosphingolipids concentrated on cell surfaces and found in abundance in the nervous system. Gangliosides have several functions, including a role in cholesterol absorption. Here is the latest research.

© 2020 Meta ULC. All rights reserved

Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice

Metabolism: Clinical and Experimental

Jan 10, 2012

Michishige TerasakiTsutomu Hirano

PMID: 22225957

DOI: 10.1016/j.metabol.2011.11.011

Abstract

We recently discovered that glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide can both prevent the development of atherosclerosis in apolipoprotein E-null (Apoe(-/-)) mice. In the present study, we attempted to extend these findings to orally administered dipeptid...read more

Mentioned in this Paper

Macrophages, Peritoneal
Glucagon (rDNA)
Epicholesterol
ZGLP1 wt Allele
Apolipoprotein Measurement
Systolic Blood Pressure Measurement
Analog
Pyrrolidines
Total cholesterol
LDL-1

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References10
  • Citations30
1
  • References10
  • Citations30
123
/papers/effects-of-pkf275-055-a-dipeptidyl-peptidase-4/22225957